HOME > TOP STORIES

TOP STORIES

REGULATORY EAD Director to Personally Visit Hospitals to Urge Early Price Agreement

August 5, 2013
BUSINESS Apo Plus to Hire 1,000 Contract MRs by 2013-End

August 2, 2013
REGULATORY Distribution Reform and Perpetuation of Premium for New Drug Development Are Immediate Top-Priority Issues: EAD Director Jo

August 2, 2013
REGULATORY CSIMC Subcommittee Discusses Revisions of Drug Pricing Rules; Some Reps Oppose Proposed Rewards for Innovation

August 1, 2013
ACADEMIA Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe

July 31, 2013
BUSINESS Novartis’s Third-Party Probe Finds “No Evidence” Indicating Data Falsification by Ex-Employee; Truth behind Diovan Woe Not Yet Uncovered

July 30, 2013
REGULATORY PAFSC’s Second Committee Recommends Approval for Bronchial Asthma Treatment Flutiform, Others

July 29, 2013
ORGANIZATION Red Cross Hospitals to Share Information on Drug Discount Rates

July 29, 2013
REGULATORY MHLW-MEXT Joint Committee Agrees to Require Researchers to Store Clinical Research Data for Long Periods

July 26, 2013
BUSINESS OncoTherapy, Panasonic Healthcare to Codevelop Immune Monitoring System to Evaluate Effects of Cancer Vaccines

July 26, 2013
REGULATORY MHLW Might Submit Bill on Online OTC Sales to Extraordinary Diet Session: PFSB Head

July 25, 2013
BUSINESS Otsuka to Develop Sensor-Embedded Abilify to Improve Drug Compliance

July 24, 2013
REGULATORY Pilot Program for Japan-Version “Compassionate Use” System to Begin at National Cancer Center

July 23, 2013
REGULATORY 1st Committee to Discuss Approval of New Products Including Janssen’s Extended Release Schizophrenia Treatment

July 23, 2013
REGULATORY MHLW Mulls “Ultra-Orphan” Drug System; Designation Might Become Possible with Pre-Clinical, Healthy Subject Data

July 22, 2013
REGULATORY US Aims for Lifting of Ban on Mixed Care: Prof. Murakami of Yamagata University

July 22, 2013
ORGANIZATION FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules

July 19, 2013
REGULATORY South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020

July 19, 2013
BUSINESS Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines

July 18, 2013
ACADEMIA University’s Seriousness to Unravel Diovan Saga Called into Question

July 17, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…